Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (4822)	11/21/1997 4:19:00 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 17367

Off Topic: I had the opportunity to visit with the science director for ARNX this morning. He was very positive about the pipe line of drugs that they have in various trial stages. They expect to file a NDA for NYOTRAN in the near future.They also expect to file for drug approval for one of their compounds in Spain in the very near future. They also have a drug(Atragen) that they expect to file for NDA. This particular drug will probably compete with LGND for the Kaposi's sarcoma market. Have you ever looked at ARNX and do you have an opinion?

To: Andrew H who wrote (4822)	11/21/1997 4:27:00 PM
From: aknahow	Respond to of 17367

Andy, seriously everything works fast. However the first time I logged in with the password it did take a long time to get to the page were quotes are available. Does the price action and volume on a certain co mean that that there is neither much interest in buying or in selling? When you search for the new site I just started on an unnamed co, just leave the search box blank, otherwise you won't get there from here. Sorry, the impact of seeing all those articles on bpi has just been too much.<g>